Cryoport, Inc. (CYRX) is a leading provider of cryogenic logistics solutions to the life sciences industry, a key component in transporting products such as regenerative medicine, gene therapies, and vaccines. Founded in 1999, the California-based company provides critical temperature-controlled logistics services to biopharmaceutical, IVF, and surrogacy industries worldwide through a network of locations and logistics partners.
Known for its advanced tracking and monitoring capabilities, Cryoport's logistics platform capitalises on cutting-edge technology, such as cloud-based logistics management software. This enables real-time monitoring of the shipment's condition, making corrections as necessary to ensure the quality and safety of the transported material.
Cryoport utilizes scientific shipping containers capable of maintaining temperatures as low as -196°C, necessary for the transportation of biological materials, including cell therapies and vaccines. The company's robust 'chain of condition' and 'chain of custody' procedures demonstrate its commitment towards maintaining the viability of sensitive biological materials throughout the transportation process.
In recent years, Cryoport has experienced significant growth, fueled by the rise in cell and gene therapies. The launch of new therapies, combined with an increasing number of clinical trials around the world, propels demand for the company’s highly specialized logistics services. Cryoport's services have also been instrumental in the global distribution of COVID-19 vaccines, cementing their importance in public health crises.
The company’s comprehensive risk management approach is highlighted by their logistics support for clinical trials and commercial launches. They ensure that biological materials reach their destination safely, utilizing advanced packaging and dedicated logistics centers.
Cryoport, Inc. is part of an innovative and rapidly growing industry that plays a crucial role in a new era of medicine, including cell and gene therapies. With the life sciences landscape continually evolving, Cryoport's services are expected to be increasingly in demand, making the company a significant player in this space. Its commitment to technological innovation and industry-leading customer service make Cryoport a trusted partner for life sciences companies around the globe.
By leveraging advanced technology, environmental sustainability, and rigorous tracking systems, Cryoport, Inc. continually pushes the boundaries of cryogenic logistics. Through innovation and dedicated service, the company remains steadfast in its mission to support the life sciences industry in delivering life-saving therapies to patients worldwide. Their key role in global health logistics firmly establishes them as leaders within the industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cryoport, Inc. announced it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, after U.S. markets close. The company will also issue a "Cryoport Third Quarter 2026 in Review" document and host a questions and answers conference call at 5:00 p.m. ET on the same day.
Cryoport is expanding its Paris Global Supply Chain Center (GSCC) to include BioServices, aiming to enhance support for advanced therapy medicinal products (ATMPs) in Europe. This expansion will integrate biostorage, custom kit production, packaging, labeling, and Qualified Person (QP) services, complementing existing French BioServices Centers. The new offering focuses on improving operational efficiency for clinical and commercial programs by providing comprehensive supply chain solutions at every development stage.
Assenagon Asset Management S.A. reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 19.3% in the third quarter, selling 222,830 shares but retaining a significant holding valued at $16.17 million. Despite missing earnings per share estimates, CryoPort's revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $19.33. The company, which provides temperature-controlled supply chain solutions for life sciences, continues to operate with negative margins, with a CEO insider sale also noted.
CryoPort (NASDAQ: CYRX) reported strong Q2 2026 results with $49 million in revenue, driven by a 15% growth in Life Science Services and a 9% increase in commercial cell and gene therapy support. The company achieved a positive adjusted EBITDA of $400,000, marking progress towards profitability, and reaffirmed its full-year revenue guidance of $192 to $196 million. Operational highlights included expanding IntegriCell cryopreservation services and launching new products, with strategic developments in China and the adoption of AI to enhance efficiency.
Nine brokerages covering CryoPort, Inc. (NASDAQ:CYRX) have issued a "Moderate Buy" consensus recommendation, with an average 1-year price target of $18.38, compared to its recent opening price of $16.90. The company reported slightly missed earnings estimates but exceeded revenue forecasts in its latest quarter and remains unprofitable. CEO Jerrell Shelton recently sold 28,800 shares, while institutional investors hold a significant 92.9% stake in the life sciences logistics company.
This article provides a technical analysis of Cryoport Inc. (NASDAQ: CYRX) trends using AI models. It highlights strong sentiment supporting an overweight bias, an exceptional risk-reward setup, and offers distinct trading strategies including Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Guggenheim maintained its 'Buy' rating for CryoPort (CYRX) and raised its price target from $16.00 to $19.00, indicating confidence in the company's growth potential within the life sciences supply chain sector. Despite the positive analyst rating, CryoPort is considered significantly overvalued by GuruFocus, with a GF Value™ of $9.62 against a current price of $17.39, suggesting a lack of margin of safety for investors. Insider selling activity and a low profitability rank also advise caution, even as the company shows strong growth potential and momentum.